Connect with us

Business

U.K. Researchers Launch Study Exploring Weed’s Effects on the Brain

Published

on

A new study to be completed by researchers in the United Kingdom will explore how cannabis affects the human brain.

Researchers in the United Kingdom are currently recruiting volunteers for a study designed to explore the effects of cannabis on the human brain. Subjects selected for the full study will be paid for their participation in the research, which is being undertaken as part of King’s College London’s Cannabis & Me project.

The researchers conducting the study have said that the research is “paramount” to understanding the science behind cannabis, which they say is used daily by approximately 200 million people worldwide and is subject to legalization efforts in countries around the globe. Dr. Marta Di Forti, a leading cannabis and psychosis researcher and the leader of the new study, noted that “Cannabis is consumed daily by many recreationally but also for medicinal reasons.” 

“But in the UK, the prescription of medicinal cannabis remains rare,” Di Forti added, as quoted by the Daily Mail. “Our study aims to provide data and tools that can make physicians in the UK and across the world more confident, where appropriate, in prescribing cannabis safely.”

To conduct the two-part study, researchers are recruiting 6,000 volunteers aged 18 to 45 who live in London. Participants selected for the study must either be regular cannabis users, have never tried the drug, or have used cannabis fewer than three times. 

The first part of the study involves a 40-minute online survey. Those who complete the initial survey will be entered into a drawing. Researchers will then select participants to complete a face-to-face assessment. Those who complete the in-person assessment will be paid £50 (nearly $60).

The preliminary questionnaire will ask participants about their experience with cannabis and why they take it, including use prompted by trauma, medical conditions, or social situations. The survey will also explore how mood and anxiety can change the way participants think and feel and influence their use of cannabis, particularly in social situations. 

Face-To-Face Assessments for Some Participants

From the survey participants, the researchers will select a subgroup of volunteers to complete a face-to-face assessment at the Institute of Psychiatry Psychology and Neuroscience at King’s College London. This portion of the study consists of three parts including a more detailed survey, a blood test and a virtual reality everyday scenario. The second questionnaire will delve into participants’ experiences with situations including trauma or adversity. Volunteers will also be asked if their consumption of cannabis has changed since they completed the original survey. 

The blood test will be used to determine levels of THC and CBD in the participants. The blood test will also be used to quantify similar compounds naturally produced by the body known as endocannabinoids to determine if the level of these substances varies among cannabis users and non-users. Additionally, the blood analysis will give the researchers data on gene structure and epigenetics, which are changes in how genes are expressed. Di Forti noted that other research suggests that tobacco smokers have epigenetic changes, but there is no research exploring if cannabis can cause similar changes.

The last part of the study will utilize virtual reality technology to put participants in a common, day-to-day scenario such as a visit to a supermarket. The study subjects will also answer questions before and after the virtual reality experience to determine how they respond to social interactions. 

A separate study will collect the same information from people undergoing treatment for psychosis believed to be caused by cannabis. Di Forti said that the goal of this portion of the research is to determine if there are biological factors that could make a person more susceptible to psychosis brought on by cannabis use, which has been observed in some patients. With the information, it is hoped that those who can use cannabis safely can be identified.

London residents interested in participating in the study can complete an initial screening survey online

Source: https://hightimes.com/news/u-k-researchers-launch-study-exploring-weeds-effects-on-the-brain/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News